Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study.

Cameron, D A; Cornbleet, M C; Mackie, R M; Hunter, J A; Gore, M; Hancock, B; Smyth, J F

Cameron, D A; Cornbleet, M C; Mackie, R M; Hunter, J A; Gore, M; Hancock, B; Smyth, J F.

Affiliation

Cameron DA; Western General Hospital, Edinburgh, United Kingdom.

Br J Cancer ; 84(9): 1146-9, 2001 May 04.

Article in En | MEDLINE | ID: mdl-11379605

Subject(s)

Antineoplastic Agents/therapeutic use; Interferon-alpha/therapeutic use; Melanoma/drug therapy; Skin Neoplasms/drug therapy; Adult; Antineoplastic Agents/pharmacology; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha/administration & dosage; Melanoma/surgery; Recombinant Proteins; Skin Neoplasms/surgery

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Interferon-alpha / Melanoma / Antineoplastic Agents Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Adult / Humans Language: En Journal: Br J Cancer Year: 2001 Document type: Article Affiliation country: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google